KMT2A and precursor B-cell acute lymphoblastic leukemia: In contrast, we found the expression of HH pathway components is a feature of both good risk (i.e., t(12;22) and poor risk (i.e., MLL-rearranged or Ph+) subtypes of B-ALL.